Home » Newsletters » BioWorld Science

BioWorld Science

March 18, 2013

View Archived Issues

Dalesconol B exerts neuroprotective effects, attenuates memory deficits in models of Alzheimer's

A novel glycooptimized biobetter of cetuximab is well tolerated in first-in-human trials

Research gives insight into miR-17-5p's role in the pathogenesis of pediatric SLE

Oncodesign's IMODI project wins award from French government

Anti-osteopontin antibodies as a new therapeutic approach to MS

Volociximab administered with ranibizumab in phase I/II trial

Targeting DNA repair with ATX-101 for enhancing sensitivity to anticancer drugs

AMAG Pharmaceuticals reports preliminary data from ferumoxytol extension study

Diffusion Pharmaceuticals completes enrollment in phase II trans-sodium crocetinate trial

LDK-378 receives FDA breakthrough therapy designation for NSCLC

Omni Bio Pharmaceutical reports preclinical results for Fc-AAT

Ocriplasmin approved for treating vitreomacular traction in the E.U.

Novel CETP inhibitors patented at Merck & Co.

GlaxoSmithKline presents new FAS inhibitors

Merck & Co. announces novel beta-secretase inhibitors

Chinese investigators divulge new cancer therapies

Novel serotonin 5-HT transporter inhibitors disclosed by Danish group

Gelna Biopharma acquires U.S. rights to Abstral

Intravesical imiquimod found safe and feasible as intravesical therapy for bladder cancer

R-Tech Ueno begins enrollment in phase III study of unoprostone for retinitis pigmentosa

Merck KGaA and Nordic Bioscience form alliance to develop treatment for osteoarthritis of the knee

BIIB-037 well tolerated in patients with Alzheimer's disease

Harvard's Wyss Institute and Sony DADC enter collaboration for Organs-on-Chips technologies

OphthaliX completes patient enrollment for international phase III trial in dry eye syndrome

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...